title: Baseline differences in the SAVOR trial.
authors.affiliation: Department of General Practice, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.
authors.forename: H J
authors.initials: HJ
authors.lastname: Luijendijk
authors.affiliation: Department of General Practice, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.
authors.forename: T A
authors.initials: TA
authors.lastname: Hulshof
mesh_terms: D000218:Adamantane / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D035843:Biomedical Research; D048909:Diabetes Complications / Q000139:chemically induced / Q000453:epidemiology / Q000401:mortality / Q000517:prevention & control; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D004151:Dipeptides / Q000009:adverse effects* / Q000627:therapeutic use; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D012107:Research Design; D012306:Risk; D015983:Selection Bias; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D004151:Dipeptides; D054873:Dipeptidyl-Peptidase IV Inhibitors; C502994:saxagliptin; D000218:Adamantane